FROM MUTATIONAL SIGNATURES TO CANCER PREVENTION: A FOCUS AROUND THE MUTOGRAPHS STUDY

11-12 July 2019 – IARC auditorium, ground floor

AGENDA

DAY 1	– Thursday 11 th July
8:30	On-site registration in IARC lobby
	WELCOME AND INTRODUCTION
	CHAIR: PAUL BRENNAN
9:00	Welcome and meeting overview Paul Brennan, Elisabete Weiderpass
9:20	What is the background to the Mutographs project? Mike Stratton
9:40	The Grand Challenge scheme Ian Walker
9:55	What is a mutational signature? Reference set of mutational signatures from human cancer (PCAWG initiative) – 15' Ludmil Alexandrov Mutational signatures of environmental exposures (COMSIG consortium) – 15' David Phillips
10:25	5000 cancers in 5 continents: where are we? Paul Brennan
10:45	Group photos and coffee break
	SCIENTIFIC UPDATES – PART 1
11:15	FOCUS ON OESOPHAGEAL CANCER CHAIR: MIKE STRATTON Lessons from the Golestan cohort study – 20' <i>Reza Malekzadeh</i> Learning from signatures in Barrett's and oesophageal adenocarcinoma: a work in progress – 20' <i>Rebecca Fitzgerald</i> From DNA to mutational signatures – 20' <i>Sarah Moody</i> Signature attribution and implications – 20' <i>Sergey Senkin</i> APOBEC mutagenesis – 20' <i>Mia Petljak</i>
13:00	Lunch – cafeteria 12 th floor
14:00	MUTATIONAL SIGNATURES FROM OTHER CANCERS CHAIR: ALLAN BALMAIN Aristolochic acid signature in liver cancer – 20' Steve Rozen The epigenomes of the cell-of-origin are recorded in the cancer genome – 20' Paz Polak The Sherlock-lung study – 20' Tere Landi
15:00	ANALYTICAL STANDARDIZATION: INSIGHTS FROM MUTOGRAPHS CHAIR: DAVID PHILLIPS Overview of SigProfiler tools – 20' Erik Bergstrom Insights from pathological reviews – 20' Behnoush Abedi-Ardekani

PERSPECTIVES

CHAIR: STEPHEN CHANOCK

16:10	Clinical implementation
	Path to diagnostics – 20'
	Manuel Salto-Tellez
	Signatures for disease and variant classification – 20'
	William Foulkes
	Tailoring treatment for pancreatic cancer – 20'
	Andrew Biankin
17:10	DAY 1 CONCLUDING REMARKS
	CHAIR: PAUL BRENNAN & MIKE STRATTON
17:20	End of meeting

20:00 Cocktail dinner

DAY 2 – Friday 12th July

	SCIENTIFIC UPDATES – PART 2
8:45	EXPERIMENTAL SIGNATURES CHAIR: JIRI ZAVADIL Modelling mutation spectra of Human carcinogens – 15' Arnoud Boot Experimental modelling reveals new characteristics of mutational signatures – 20' Jiri Zavadil Mutographs repertoire of experimental signatures – 20' Allan Balmain Organoids: lessons from Mutographs – 20' David Phillips
10:00	Coffee break and Poster session (Princess Takamatsu Hall)
11:00	Poster prizes Stephen Chanock
11:05	FIELDWORK CHAIR: LOUISE WALKER Barretos Cancer Hospital experience – 20' <i>Rui Reis</i> Emerging aetiology of ESCC in East Africa – 20' Valerie McCormack The patients' perspective – 20' Mimi McCord & Maggie Blanks
12:05	MUTATIONAL LANDSCAPE OF NORMAL & PRECANCEROUS TISSUES CHAIR: PETER CAMPBELL New insights from Mutographs liver and lung work – 25' Peter Campbell Breast cancer update – 15' Tim Butler Precancerous signatures – 15' Phoebe He
13:00	Lunch – cafeteria 12 th floor

GENERAL DISCUSSION

	CHAIR: LUDMIL ALEXANDROV
14:00	The future of Mutographs collaborations The Clinician's point of view: Potential of germline genetic susceptibility in diverse populations – 15' Patricia Prolla The Pathologist's point of view: introduction of Optimisticc and links with Mutographs – 15' Philip Quirke The Omics experts' point of views: How epigenetic influences the cancer genome – 15' Tatsuhiro Shibata How adductomics can inform cancer etiology – 15' Yukari Totsuka Grand Challenge Scientific Advisory Panel point of view – 15' Ed Harlow
15:15	The complexity of the art and science of mutational signatures Stephen Chanock
16:00	End of meeting